1. Home
  2. ZLAB vs CNXC Comparison

ZLAB vs CNXC Comparison

Compare ZLAB & CNXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZLAB
  • CNXC
  • Stock Information
  • Founded
  • ZLAB 2013
  • CNXC 1991
  • Country
  • ZLAB China
  • CNXC United States
  • Employees
  • ZLAB N/A
  • CNXC N/A
  • Industry
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • CNXC Computer Software: Prepackaged Software
  • Sector
  • ZLAB Health Care
  • CNXC Technology
  • Exchange
  • ZLAB Nasdaq
  • CNXC Nasdaq
  • Market Cap
  • ZLAB 3.0B
  • CNXC 3.0B
  • IPO Year
  • ZLAB 2017
  • CNXC N/A
  • Fundamental
  • Price
  • ZLAB $26.91
  • CNXC $42.31
  • Analyst Decision
  • ZLAB Strong Buy
  • CNXC Buy
  • Analyst Count
  • ZLAB 4
  • CNXC 5
  • Target Price
  • ZLAB $52.50
  • CNXC $79.00
  • AVG Volume (30 Days)
  • ZLAB 960.6K
  • CNXC 740.8K
  • Earning Date
  • ZLAB 11-12-2024
  • CNXC 01-22-2025
  • Dividend Yield
  • ZLAB N/A
  • CNXC 3.16%
  • EPS Growth
  • ZLAB N/A
  • CNXC N/A
  • EPS
  • ZLAB N/A
  • CNXC 3.08
  • Revenue
  • ZLAB $355,748,000.00
  • CNXC $9,401,638,000.00
  • Revenue This Year
  • ZLAB $48.50
  • CNXC $37.81
  • Revenue Next Year
  • ZLAB $47.37
  • CNXC $2.26
  • P/E Ratio
  • ZLAB N/A
  • CNXC $13.79
  • Revenue Growth
  • ZLAB 35.01
  • CNXC 44.09
  • 52 Week Low
  • ZLAB $13.48
  • CNXC $36.28
  • 52 Week High
  • ZLAB $36.60
  • CNXC $106.10
  • Technical
  • Relative Strength Index (RSI)
  • ZLAB 45.71
  • CNXC 47.55
  • Support Level
  • ZLAB $25.85
  • CNXC $41.65
  • Resistance Level
  • ZLAB $29.87
  • CNXC $47.56
  • Average True Range (ATR)
  • ZLAB 1.05
  • CNXC 1.92
  • MACD
  • ZLAB -0.18
  • CNXC -0.04
  • Stochastic Oscillator
  • ZLAB 21.98
  • CNXC 27.58

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

About CNXC Concentrix Corporation

Concentrix Corp is a technology-enabled company specialized in customer engagement and customer management. The company provides end-to-end capabilities, including CX process optimization, technology innovation and design engineering, front- and back-office automation, analytics and business transformation services to clients in five primary industry verticals. The Company's verticals are technology and consumer electronics, retail, travel and e-commerce, communications and media, banking, financial services and insurance, and healthcare. Geographically, the company operates in Philippines, Unites States, India, Canada, Germany, Great Britain and others.

Share on Social Networks: